Literature DB >> 23303902

Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.

Malin Pedersen1, Heidi V N Küsters-Vandevelde2, Amaya Viros1, Patricia J T A Groenen3, Berta Sanchez-Laorden1, Jacobus H Gilhuis4, Ilse A van Engen-van Grunsven2, Willy Renier5, Jolanda Schieving6, Ion Niculescu-Duvaz7, Caroline J Springer7, Benno Küsters2, Pieter Wesseling2,3,8, Willeke A M Blokx3, Richard Marais1,9.   

Abstract

UNLABELLED: NRAS mutations are common in human melanoma. To produce a mouse model of NRAS-driven melanoma, we expressed oncogenic NRAS (NRAS(G12D)) in mouse melanocytes. When NRAS(G12D) was expressed in the melanocytes of developing embryos, it induced melanocyte proliferation and congenital melanocytic lesions reminiscent of human blue nevi but did not induce cutaneous melanoma. Unexpectedly, however, it did induce early-onset primary melanoma of the central nervous system (CNS). The tumors were rapidly proliferating and caused neurologic symptoms, rapid health deterioration, and death. NRAS is not a common driver oncogene of primary melanoma of the CNS in adults, but we report two cases of primary melanoma of the CNS in children, both of which carried oncogenic mutations in NRAS. We conclude that acquisition of somatic mutations in NRAS in CNS melanocytes is a predisposing risk factor for primary melanoma of the CNS in children, and we present a mouse model of this disease. SIGNIFICANCE: We show that the acquisition of NRAS mutations in melanocytes during embryogenesis is a risk factor for early-onset melanoma of the CNS. We have developed a powerful mouse model to study this rare but devastating childhood disease, and to develop therapeutic approaches for its treatment. ©2013 AACR.

Entities:  

Mesh:

Year:  2013        PMID: 23303902      PMCID: PMC3999382          DOI: 10.1158/2159-8290.CD-12-0464

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  40 in total

1.  GNAQ and GNA11 mutations in melanocytomas of the central nervous system.

Authors:  Rajmohan Murali; Thomas Wiesner; Marc K Rosenblum; Boris C Bastian
Journal:  Acta Neuropathol       Date:  2012-02-04       Impact factor: 17.088

2.  Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.

Authors:  Olga Shakhova; Daniel Zingg; Simon M Schaefer; Lisette Hari; Gianluca Civenni; Jacqueline Blunschi; Stéphanie Claudinot; Michal Okoniewski; Friedrich Beermann; Daniela Mihic-Probst; Holger Moch; Michael Wegner; Reinhard Dummer; Yann Barrandon; Paolo Cinelli; Lukas Sommer
Journal:  Nat Cell Biol       Date:  2012-07-08       Impact factor: 28.824

3.  Mutations in GNA11 in uveal melanoma.

Authors:  Catherine D Van Raamsdonk; Klaus G Griewank; Michelle B Crosby; Maria C Garrido; Swapna Vemula; Thomas Wiesner; Anna C Obenauf; Werner Wackernagel; Gary Green; Nancy Bouvier; M Mert Sozen; Gail Baimukanova; Ritu Roy; Adriana Heguy; Igor Dolgalev; Raya Khanin; Klaus Busam; Michael R Speicher; Joan O'Brien; Boris C Bastian
Journal:  N Engl J Med       Date:  2010-11-17       Impact factor: 91.245

4.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

5.  Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.

Authors:  L Chin; J Pomerantz; D Polsky; M Jacobson; C Cohen; C Cordon-Cardo; J W Horner; R A DePinho
Journal:  Genes Dev       Date:  1997-11-01       Impact factor: 11.361

6.  Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi.

Authors:  J Carr; R M Mackie
Journal:  Br J Dermatol       Date:  1994-07       Impact factor: 9.302

Review 7.  Congenital melanocytic naevi.

Authors:  Ivanka Kovalyshyn; Ralph Braun; Ashfaq Marghoob
Journal:  Australas J Dermatol       Date:  2009-11       Impact factor: 2.875

Review 8.  Cutaneous melanoma in genetically modified animals.

Authors:  Lionel Larue; Friedrich Beermann
Journal:  Pigment Cell Res       Date:  2007-12

9.  Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Authors:  Leisl M Packer; Sareena Rana; Robert Hayward; Thomas O'Hare; Christopher A Eide; Ana Rebocho; Sonja Heidorn; Matthew S Zabriskie; Ion Niculescu-Duvaz; Brian J Druker; Caroline Springer; Richard Marais
Journal:  Cancer Cell       Date:  2011-12-13       Impact factor: 31.743

10.  Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.

Authors:  Heidi V N Küsters-Vandevelde; Annelies Klaasen; Benno Küsters; Patricia J T A Groenen; Ilse A C H van Engen-van Grunsven; Marcory R C F van Dijk; Guido Reifenberger; Pieter Wesseling; Willeke A M Blokx
Journal:  Acta Neuropathol       Date:  2010-03       Impact factor: 17.088

View more
  28 in total

1.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

2.  Pericyte Ontogeny: The Use of Chimeras to Track a Cell Lineage of Diverse Germ Line Origins.

Authors:  Heather C Etchevers
Journal:  Methods Mol Biol       Date:  2021

3.  Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Authors:  Christin E Burd; Wenjin Liu; Minh V Huynh; Meriam A Waqas; James E Gillahan; Kelly S Clark; Kailing Fu; Brit L Martin; William R Jeck; George P Souroullas; David B Darr; Daniel C Zedek; Michael J Miley; Bruce C Baguley; Sharon L Campbell; Norman E Sharpless
Journal:  Cancer Discov       Date:  2014-09-24       Impact factor: 39.397

4.  Can Combination MEK and Akt Inhibition Slay the Giant Congenital Nevus?

Authors:  Brandon M Murphy; Christin E Burd
Journal:  J Invest Dermatol       Date:  2019-09       Impact factor: 8.551

5.  Mutations in g protein encoding genes and chromosomal alterations in primary leptomeningeal melanocytic neoplasms.

Authors:  Heidi V N Küsters-Vandevelde; Ilse A C H van Engen-van Grunsven; Sarah E Coupland; Sarah L Lake; Jos Rijntjes; Rolph Pfundt; Benno Küsters; Pieter Wesseling; Willeke A M Blokx; Patricia J T A Groenen
Journal:  Pathol Oncol Res       Date:  2014-10-15       Impact factor: 3.201

Review 6.  Genetically engineered mouse models of melanoma.

Authors:  Eva Pérez-Guijarro; Chi-Ping Day; Glenn Merlino; M Raza Zaidi
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

7.  Topical therapy for regression and melanoma prevention of congenital giant nevi.

Authors:  Yeon Sook Choi; Tal H Erlich; Max von Franque; Inbal Rachmin; Jessica L Flesher; Erik B Schiferle; Yi Zhang; Marcello Pereira da Silva; Alva Jiang; Allison S Dobry; Mack Su; Sharon Germana; Sebastian Lacher; Orly Freund; Ezra Feder; Jose L Cortez; Suyeon Ryu; Tamar Babila Propp; Yedidyah Leo Samuels; Labib R Zakka; Marjan Azin; Christin E Burd; Norman E Sharpless; X Shirley Liu; Clifford Meyer; William Gerald Austen; Branko Bojovic; Curtis L Cetrulo; Martin C Mihm; Dave S Hoon; Shadmehr Demehri; Elena B Hawryluk; David E Fisher
Journal:  Cell       Date:  2022-05-12       Impact factor: 66.850

8.  Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.

Authors:  Christian Posch; Martina Sanlorenzo; Igor Vujic; Juan A Oses-Prieto; Brian D Cholewa; Sarasa T Kim; Jeffrey Ma; Kevin Lai; Mitchell Zekhtser; Rosaura Esteve-Puig; Gary Green; Shreya Chand; Alma L Burlingame; Renate Panzer-Grümayer; Klemens Rappersberger; Susana Ortiz-Urda
Journal:  J Invest Dermatol       Date:  2016-05-29       Impact factor: 8.551

9.  Hiding in plain sight: molecular genetics applied to giant congenital melanocytic nevi.

Authors:  Heather C Etchevers
Journal:  J Invest Dermatol       Date:  2014-04       Impact factor: 8.551

Review 10.  The Evolution of Melanoma - Moving beyond Binary Models of Genetic Progression.

Authors:  Hanlin Zeng; Robert L Judson-Torres; A Hunter Shain
Journal:  J Invest Dermatol       Date:  2019-10-14       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.